Tag: Bioasis

June 26, 2019 Off

Bioasis completes pre-IND process

Bioasis submitted to the FDA its pre-IND briefing document in support of the xB3-001 program for the treatment of patients with confirmed human epidermal growth factor receptor 2 (“HER2”)-positive (“HER2+”) breast cancer and brain metastases.

June 24, 2019 Off

Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications

By BusinessWire

U.S. Patent Office and European Patent Office issue allowances of patent applications relating to iduronate-2-sulfatase (“IDS”) polypeptide/xB3 conjugates European Patent…